Advances in hyperprogressive disease of PD-1/PD-L1 antibody drugs and rational drug therapy
10.16438/j.0513-4870.2019-0569
- VernacularTitle:靶向肿瘤PD-1/PD-L1抗体药物治疗中出现疾病“超进展”现象及其合理应用研究进展
- Author:
Si-chen YUAN
1
;
Hui-feng ZHAO
1
;
Hao-shu WU
1
;
Ji CAO
1
Author Information
1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
- Publication Type:Research Article
- Keywords:
programmed cell death 1;
programmed cell death 1 ligand 1;
hyperprogressive disease;
biomarker;
rational drug therapy
- From:
Acta Pharmaceutica Sinica
2019;54(10):1735-1740
- CountryChina
- Language:Chinese
-
Abstract:
With the significant breakthrough that programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) antibody drugs achieved promising clinical outcomes across various tumor types, immunotherapy targeting immune checkpoint has been considered a promising way to treat cancer. However, most recently studies suggest that the hyperprogressive disease occurred frequently during the therapy of using PD-1/PD-L1 antibody drugs and has become an urgent problem to be solved. In this review, we summarize the progress and potential reasons of hyperprogressive disease caused by PD-1/PD-L1 blockade, and further discuss its application based on the rational use of biomarkers for searching the benefit patients.
